Physician profile
Robert Sprung
NPI 1255314837
$1,215.70
in general payments reported to CMS, 2019-2025
14 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $192 · 2021: $188 · 2022: $157 · 2023: $70.64 · 2024: $279 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $410.56 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $140.60 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $108.24 | 2020-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $108.17 | 2021-2024 | |
| Viatris Specialty LLC | $106.68 | 2025 | Yupelri |
| Amgen INC. | $71.82 | 2020-2022 | |
| Glaxosmithkline, LLC. | $60.07 | 2021-2023 | Nucala |
| Merck Sharp & Dohme LLC | $56.23 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.05 | 2019-2020 | |
| Pfizer INC. | $34.87 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $22.45 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $21.64 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $20.68 | 2025 | |
| Novo Nordisk INC | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sprung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.